Athersys Stock Price, News & Analysis (NASDAQ:ATHX)

$1.67 0.00 (0.00 %)
(As of 12/18/2017 12:57 PM ET)
Previous Close$1.67
Today's Range$1.66 - $1.72
52-Week Range$1.02 - $2.63
Volume787,100 shs
Average Volume1.01 million shs
Market Capitalization$197.95 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.38

About Athersys (NASDAQ:ATHX)

Athersys logoAthersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATHX
CUSIPN/A
Phone216-431-9900

Debt

Debt-to-Equity RatioN/A
Current Ratio4.71%
Quick Ratio4.71%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.35 million
Price / Sales11.41
Cash FlowN/A
Price / CashN/A
Book Value$0.13 per share
Price / Book12.85

Profitability

Trailing EPS($0.28)
Net Income$-15,330,000.00
Net Margins-746.04%
Return on Equity-113.63%
Return on Assets-86.25%

Miscellaneous

Employees60
Outstanding Shares118,530,000

Athersys (NASDAQ:ATHX) Frequently Asked Questions

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) posted its quarterly earnings data on Tuesday, August, 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $0.32 million. Athersys had a negative net margin of 746.04% and a negative return on equity of 113.63%. The business's revenue was up 200.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.05) EPS. View Athersys' Earnings History.

When will Athersys make its next earnings announcement?

Athersys is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Athersys.

Where is Athersys' stock going? Where will Athersys' stock price be in 2017?

3 Wall Street analysts have issued 1 year price objectives for Athersys' stock. Their forecasts range from $7.00 to $12.00. On average, they expect Athersys' stock price to reach $9.50 in the next year. View Analyst Ratings for Athersys.

What are Wall Street analysts saying about Athersys stock?

Here are some recent quotes from research analysts about Athersys stock:

  • 1. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (10/10/2017)
  • 2. Maxim Group analysts commented, "A negative blogger blasted Athersys Multistem with Zombie" like properties as a therapeutic that just won’t die. The article (in our opinion) picks and chooses elements of the Athersys story which when taken out of context paint a confusing picture." (10/5/2017)

Who are some of Athersys' key competitors?

Who are Athersys' key executives?

Athersys' management team includes the folowing people:

  • Gil Van Bokkelen Ph.D., Chairman of the Board, Chief Executive Officer (Age 56)
  • William B.J. Lehmann Jr. J.D., President, Chief Operating Officer (Age 51)
  • John J. Harrington Ph.D., Executive Vice President, Chief Scientific Officer, Director (Age 49)
  • Laura K. Campbell CPA, Senior Vice President - Finance (Age 53)
  • Lee E. Babiss Ph.D., Lead Independent Director (Age 61)
  • Jordan S. Davis, Independent Director (Age 55)
  • Ismail Kola, Independent Director (Age 60)
  • Lorin Jeffry Randall, Independent Director (Age 73)
  • Jack L. Wyszomierski, Independent Director (Age 61)

Who owns Athersys stock?

Athersys' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Mckinley Capital Management LLC Delaware (0.45%), Bank of New York Mellon Corp (0.28%), Perkins Capital Management Inc. (0.27%), Wells Fargo & Company MN (0.15%), Schwab Charles Investment Management Inc. (0.13%) and NEXT Financial Group Inc (0.11%). Company insiders that own Athersys stock include Ismail Kola, John J Harrington, Laura K Campbell, William Lehmann Jr and William Lehmann, Jr. View Institutional Ownership Trends for Athersys.

Who sold Athersys stock? Who is selling Athersys stock?

Athersys' stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. Company insiders that have sold Athersys company stock in the last year include John J Harrington and William Lehmann Jr. View Insider Buying and Selling for Athersys.

Who bought Athersys stock? Who is buying Athersys stock?

Athersys' stock was bought by a variety of institutional investors in the last quarter, including Mckinley Capital Management LLC Delaware, Perkins Capital Management Inc., OxFORD Asset Management LLP, Thompson Davis & CO. Inc., Wells Fargo & Company MN, Bank of New York Mellon Corp and NEXT Financial Group Inc. Company insiders that have bought Athersys stock in the last two years include Ismail Kola and Laura K Campbell. View Insider Buying and Selling for Athersys.

How do I buy Athersys stock?

Shares of Athersys can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athersys' stock price today?

One share of Athersys stock can currently be purchased for approximately $1.67.

How big of a company is Athersys?

Athersys has a market capitalization of $197.95 million and generates $17.35 million in revenue each year. The biopharmaceutical company earns $-15,330,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Athersys employs 60 workers across the globe.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]


MarketBeat Community Rating for Athersys (ATHX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  270
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Athersys (NASDAQ:ATHX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.50$9.50$9.50$8.33
Price Target Upside: 433.71% upside433.71% upside442.86% upside455.56% upside

Athersys (NASDAQ:ATHX) Consensus Price Target History

Price Target History for Athersys (NASDAQ:ATHX)

Athersys (NASDAQ:ATHX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017Maxim GroupSet Price TargetBuy$12.00N/AView Rating Details
3/28/2017William BlairReiterated RatingOutperformHighView Rating Details
2/7/2017Needham & Company LLCInitiated CoverageBuy$7.00N/AView Rating Details
1/10/2016WBB SecuritiesReiterated RatingBuy$9.00N/AView Rating Details
(Data available from 12/18/2015 forward)

Earnings

Athersys (NASDAQ:ATHX) Earnings History and Estimates Chart

Earnings by Quarter for Athersys (NASDAQ:ATHX)

Athersys (NASDAQ ATHX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018($0.07)N/AView Earnings Details
8/9/2017Q2 2017($0.06)($0.06)$0.96 million$0.67 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.07)($0.06)$0.45 million$1.50 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.08)($0.10)$0.45 million$0.98 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.10)($0.07)$0.60 million$0.31 millionViewListenView Earnings Details
8/9/2016Q216($0.10)($0.08)$0.32 million$0.60 millionViewN/AView Earnings Details
5/5/2016Q1($0.08)$0.06$1.85 million$15.45 millionViewN/AView Earnings Details
3/10/2016Q4($0.09)$0.04$3.72 million$10.61 millionViewListenView Earnings Details
11/5/2015Q315($0.07)($0.08)$1.75 million$0.40 millionViewListenView Earnings Details
8/6/2015Q2($0.08)$0.02$2.66 million$0.22 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.16)$2.01 million$0.73 millionViewListenView Earnings Details
3/12/2015Q414($0.09)($0.08)$0.50 million$0.24 millionViewN/AView Earnings Details
11/10/2014Q314($0.09)($0.11)$0.54 million$0.29 millionViewN/AView Earnings Details
8/11/2014Q214($0.09)($0.06)$0.70 million$0.40 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.09)$0.66 million$0.71 millionViewN/AView Earnings Details
3/13/2014Q413($0.11)($0.15)$1.81 million$0.92 millionViewN/AView Earnings Details
11/14/2013Q3($0.12)($0.10)$0.49 million$0.62 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.12)($0.11)$390.00 million$0.57 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.11)($0.18)$1.58 million$0.33 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.12)$2.51 million$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Athersys (NASDAQ:ATHX) Earnings Estimates

2017 EPS Consensus Estimate: ($0.27)
2018 EPS Consensus Estimate: ($0.42)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.07)($0.07)($0.07)
Q2 20172($0.07)($0.06)($0.07)
Q3 20172($0.07)($0.06)($0.07)
Q4 20172($0.08)($0.06)($0.07)
Q1 20181($0.09)($0.09)($0.09)
Q2 20181($0.10)($0.10)($0.10)
Q3 20181($0.11)($0.11)($0.11)
Q4 20181($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Athersys (NASDAQ:ATHX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Athersys (NASDAQ ATHX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 21.06%
Insider Trades by Quarter for Athersys (NASDAQ:ATHX)
Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)

Athersys (NASDAQ ATHX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2017William Lehmann JrInsiderSell15,000$2.38$35,700.00View SEC Filing  
9/18/2017John J HarringtonEVPSell15,000$2.17$32,550.00View SEC Filing  
6/16/2017John J HarringtonEVPSell36,000$1.45$52,200.00View SEC Filing  
2/1/2017Ismail KolaDirectorBuy15,000$1.01$15,150.00View SEC Filing  
2/1/2017Laura K CampbellInsiderBuy20,000$1.01$20,200.00View SEC Filing  
12/19/2016William Lehmann JrInsiderSell3,000$1.60$4,800.00View SEC Filing  
12/16/2016John J HarringtonEVPSell15,000$1.60$24,000.00View SEC Filing  
9/19/2016William Lehmann JrInsiderSell3,000$1.96$5,880.00View SEC Filing  
9/16/2016John J HarringtonEVPSell15,000$1.96$29,400.00View SEC Filing  
6/21/2016William Lehmann JrCOOSell25,000$2.17$54,250.00View SEC Filing  
3/21/2016William Lehmann JrCOOSell25,000$2.41$60,250.00View SEC Filing  
12/21/2015William Lehmann, Jr.COOSell25,000$1.03$25,750.00View SEC Filing  
9/21/2015Bokkelen Gil VanCEOSell9,500$1.36$12,920.00View SEC Filing  
9/21/2015John J. HarringtonEVPSell8,150$1.36$11,084.00View SEC Filing  
9/21/2015William Lehmann, Jr.COOSell25,000$1.36$34,000.00View SEC Filing  
6/22/2015William Lehmann JrCOOSell25,000$1.21$30,250.00View SEC Filing  
6/19/2015John J HarringtonInsiderSell8,150$1.23$10,024.50View SEC Filing  
6/19/2015Robert J DeansEVPSell5,080$1.23$6,248.40View SEC Filing  
6/9/2015Kenneth H TraubDirectorBuy30,000$1.27$38,100.00View SEC Filing  
3/20/2015William Lehmann JrCOOSell25,000$3.14$78,500.00View SEC Filing  
3/19/2015Bokkelen Gil VanCEOSell9,500$3.10$29,450.00View SEC Filing  
3/19/2015Robert J DeansEVPSell5,080$3.10$15,748.00View SEC Filing  
12/19/2014Bokkelen Gil VanCEOSell9,500$1.29$12,255.00View SEC Filing  
12/19/2014Robert J DeansEVPSell5,080$1.28$6,502.40View SEC Filing  
12/19/2014William Lehmann JrCOOSell30,000$1.29$38,700.00View SEC Filing  
9/24/2014Kenneth H TraubDirectorBuy30,000$1.39$41,700.00View SEC Filing  
9/22/2014William Lehmann JrCOOSell30,000$1.40$42,000.00View SEC Filing  
9/19/2014Bokkelen Gil VanCEOSell9,500$1.41$13,395.00View SEC Filing  
9/19/2014John J HarringtonInsiderSell8,150$1.41$11,491.50View SEC Filing  
9/19/2014Robert J DeansEVPSell5,080$1.41$7,162.80View SEC Filing  
8/18/2014Lorin RandallDirectorSell15,000$1.54$23,100.00View SEC Filing  
6/20/2014William Lehmann JrCOOSell12,000$1.58$18,960.00View SEC Filing  
6/19/2014Bokkelen Gil VanCEOSell9,500$1.63$15,485.00View SEC Filing  
6/19/2014John J HarringtonInsiderSell8,150$1.63$13,284.50View SEC Filing  
6/19/2014Robert J DeansEVPSell5,080$1.63$8,280.40View SEC Filing  
6/19/2014William Lehmann JrCOOSell13,000$1.62$21,060.00View SEC Filing  
3/20/2014William Lehmann JrCOOSell25,000$3.62$90,500.00View SEC Filing  
3/18/2014Bokkelen Gil VanCEOSell9,500$3.54$33,630.00View SEC Filing  
3/18/2014John J HarringtonInsiderSell8,150$3.54$28,851.00View SEC Filing  
3/18/2014Robert J DeansEVPSell5,080$3.54$17,983.20View SEC Filing  
12/20/2013William Lehmann JrCOOSell25,000$2.13$53,250.00View SEC Filing  
12/11/2013Kenneth H TraubDirectorBuy20,000$1.94$38,800.00View SEC Filing  
9/20/2013John J HarringtonInsiderSell30,000$1.82$54,600.00View SEC Filing  
9/20/2013William Lehmann JrCOOSell12,000$1.83$21,960.00View SEC Filing  
11/28/2012Laura K CampbellVPBuy10,000$1.01$10,100.00View SEC Filing  
11/15/2012Robert J DeansEVPBuy3,500$0.99$3,465.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Athersys (NASDAQ ATHX) News Headlines

Source:
DateHeadline
Athersys (ATHX) Downgraded by ValuEngine to "Sell"Athersys (ATHX) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 5 at 10:50 PM
Athersys, Inc. (ATHX) Rating Increased to Hold at ValuEngineAthersys, Inc. (ATHX) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - November 23 at 12:46 AM
Maxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price TargetMaxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target
www.americanbankingnews.com - November 16 at 10:18 PM
HEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem® Treatment for Ischemic StrokeHEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem® Treatment for Ischemic Stroke
finance.yahoo.com - November 16 at 11:35 AM
 Brokerages Set $12.00 Price Target for Athersys, Inc. (ATHX) Brokerages Set $12.00 Price Target for Athersys, Inc. (ATHX)
www.americanbankingnews.com - November 13 at 7:30 PM
Stocks Under Scanner in the Biotech Space -- Sangamo Therapeutics, Vertex Pharma, Athersys, and AVEO Pharma - PR Newswire (press release)Stocks Under Scanner in the Biotech Space -- Sangamo Therapeutics, Vertex Pharma, Athersys, and AVEO Pharma - PR Newswire (press release)
www.prnewswire.com - November 10 at 1:41 PM
Edited Transcript of ATHX earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of ATHX earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 5:19 PM
Athersys Reports Third Quarter 2017 Results - GlobeNewswire (press release)Athersys Reports Third Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - November 9 at 4:29 AM
Athersys, Inc. to Host Earnings CallAthersys, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 6:24 PM
Athersys Reports Third Quarter 2017 ResultsAthersys Reports Third Quarter 2017 Results
finance.yahoo.com - November 8 at 6:24 PM
Athersys, Inc. (ATHX) Scheduled to Post Quarterly Earnings on TuesdayAthersys, Inc. (ATHX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 9:58 AM
Bears On Parade - Regardless, Athersys Is Developing Key Relationships For A Successful FutureBears On Parade - Regardless, Athersys Is Developing Key Relationships For A Successful Future
seekingalpha.com - October 14 at 2:43 AM
Featured Company News - Athersys Signs Agreement with Nikon CeLL Innovation for Commercial Manufacturing of MultiStem in JapanFeatured Company News - Athersys Signs Agreement with Nikon CeLL Innovation for Commercial Manufacturing of MultiStem in Japan
finance.yahoo.com - October 13 at 4:39 PM
Athersys Partners Up: Can Nikon CeLL Get MultiStem On Track? - Seeking AlphaAthersys Partners Up: Can Nikon CeLL Get MultiStem On Track? - Seeking Alpha
seekingalpha.com - October 13 at 2:58 AM
Athersys (ATHX) in Focus: Stock Moves 7.2% Higher - NasdaqAthersys (ATHX) in Focus: Stock Moves 7.2% Higher - Nasdaq
www.nasdaq.com - October 13 at 2:58 AM
Athersys (ATHX) in Focus: Stock Moves 7.2% HigherAthersys (ATHX) in Focus: Stock Moves 7.2% Higher
finance.yahoo.com - October 12 at 4:57 PM
Athersys Hikes on MultiStem Hookup with Japanese FirmAthersys Hikes on MultiStem Hookup with Japanese Firm
www.baystreet.ca - October 11 at 5:41 PM
Athersys (ATHX) Reports Collaboration Agreement with Nikon Cell Innovation Co. on MultiStem Commercial Manufacturing in JapanAthersys (ATHX) Reports Collaboration Agreement with Nikon Cell Innovation Co. on MultiStem Commercial Manufacturing in Japan
www.streetinsider.com - October 11 at 5:41 PM
Athersys and Nikon CeLL Innovation to Collaborate on MultiStem® Commercial Manufacturing in JapanAthersys and Nikon CeLL Innovation to Collaborate on MultiStem® Commercial Manufacturing in Japan
finance.yahoo.com - October 11 at 5:41 PM
Athersys, Inc. (ATHX) Rating Lowered to Hold at Zacks Investment ResearchAthersys, Inc. (ATHX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 10 at 5:46 PM
Mid-Day Market Update: Crude Oil Up 2.7%; MannKind Shares Spike HigherMid-Day Market Update: Crude Oil Up 2.7%; MannKind Shares Spike Higher
www.nasdaq.com - October 10 at 5:25 PM
Athersys to Host Third Quarter Financial Results CallAthersys to Host Third Quarter Financial Results Call
feeds.benzinga.com - October 9 at 11:35 AM
Athersys (ATHX) & Its Rivals Head to Head SurveyAthersys (ATHX) & Its Rivals Head to Head Survey
www.americanbankingnews.com - October 8 at 9:00 AM
William Blair Weighs in on Athersys, Inc.s Q1 2018 Earnings (ATHX)William Blair Weighs in on Athersys, Inc.'s Q1 2018 Earnings (ATHX)
www.americanbankingnews.com - October 6 at 11:04 AM
3 Things In Biotech You Should Learn Today: October 6, 20173 Things In Biotech You Should Learn Today: October 6, 2017
seekingalpha.com - October 6 at 9:07 AM
Maxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price TargetMaxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target
www.americanbankingnews.com - October 5 at 9:30 PM
Athersys (ATHX) Announces RMAT Designation From FDA - StreetInsider.comAthersys (ATHX) Announces RMAT Designation From FDA - StreetInsider.com
www.streetinsider.com - October 5 at 7:01 PM
Athersys: Cash Concerns Cast A Long Shadow - Seeking AlphaAthersys: Cash Concerns Cast A Long Shadow - Seeking Alpha
seekingalpha.com - September 28 at 4:33 PM
Insider Selling: Athersys, Inc. (ATHX) EVP Sells 15,000 Shares of StockInsider Selling: Athersys, Inc. (ATHX) EVP Sells 15,000 Shares of Stock
www.americanbankingnews.com - September 19 at 8:32 PM
Athersys, Inc. (ATHX) Insider William Lehmann, Jr. Sells 15,000 SharesAthersys, Inc. (ATHX) Insider William Lehmann, Jr. Sells 15,000 Shares
www.americanbankingnews.com - September 19 at 8:32 PM
Regulatory Alignment Reinforces Bullish Case For Athersys - Seeking AlphaRegulatory Alignment Reinforces Bullish Case For Athersys - Seeking Alpha
seekingalpha.com - September 19 at 4:09 PM
Athersys Multistem Partner Healios KK Delays Implementation Of Critical Phase III TREASURE Trial - Seeking AlphaAthersys Multistem Partner Healios KK Delays Implementation Of Critical Phase III TREASURE Trial - Seeking Alpha
seekingalpha.com - September 11 at 4:12 PM
Athersys (ATHX) in Focus: Stock Moves 10.22% Higher - NasdaqAthersys (ATHX) in Focus: Stock Moves 10.22% Higher - Nasdaq
www.nasdaq.com - September 8 at 2:12 AM
Athersys, Inc. (ATHX) Given Buy Rating at Maxim GroupAthersys, Inc. (ATHX) Given Buy Rating at Maxim Group
www.americanbankingnews.com - September 4 at 2:32 PM
Athersys, Inc. to Post Q4 2017 Earnings of ($0.08) Per Share, William Blair Forecasts (NASDAQ:ATHX)Athersys, Inc. to Post Q4 2017 Earnings of ($0.08) Per Share, William Blair Forecasts (NASDAQ:ATHX)
www.americanbankingnews.com - August 14 at 6:42 AM
Athersys, Inc. (ATHX) Posts  Earnings Results, Meets EstimatesAthersys, Inc. (ATHX) Posts Earnings Results, Meets Estimates
www.americanbankingnews.com - August 10 at 3:42 PM
Edited Transcript of ATHX earnings conference call or presentation 9-Aug-17 8:30pm GMTEdited Transcript of ATHX earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 3:35 PM
Athersys Reports Second Quarter 2017 Results - GlobeNewswire (press release)Athersys Reports Second Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 4:20 PM
Featured Company News – Athersys Reported Alignment of Key Regulators for Pivotal Registration Study in Ischemic StrokeFeatured Company News – Athersys Reported Alignment of Key Regulators for Pivotal Registration Study in Ischemic Stroke
finance.yahoo.com - August 9 at 4:20 PM
Investor Network: Athersys, Inc. to Host Earnings CallInvestor Network: Athersys, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 4:19 PM
Athersys Reports Second Quarter 2017 ResultsAthersys Reports Second Quarter 2017 Results
finance.yahoo.com - August 9 at 4:19 PM
Athersys Reports Alignment of Key Regulators for Pivotal Registration Study in StrokeAthersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke
finance.yahoo.com - August 7 at 4:56 PM
Maxim Group Analysts Give Athersys, Inc. (ATHX) a $9.00 Price TargetMaxim Group Analysts Give Athersys, Inc. (ATHX) a $9.00 Price Target
www.americanbankingnews.com - August 7 at 1:08 PM
Athersys, Inc. (ATHX) to Release Earnings on WednesdayAthersys, Inc. (ATHX) to Release Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:18 AM
Athersyss Cardiovascular Health Program Is Ambitious and Well-Calculated - Seeking AlphaAthersys's Cardiovascular Health Program Is Ambitious and Well-Calculated - Seeking Alpha
seekingalpha.com - July 28 at 10:22 PM
Athersys to Host Second Quarter Financial Results Call - GlobeNewswire (press release)Athersys to Host Second Quarter Financial Results Call - GlobeNewswire (press release)
globenewswire.com - July 10 at 4:10 PM
Athersys to Host Second Quarter Financial Results CallAthersys to Host Second Quarter Financial Results Call
finance.yahoo.com - July 10 at 4:10 PM
 Athersys, Inc. (NASDAQ:ATHX) Receives Consensus Recommendation of "Strong Buy" from Brokerages Athersys, Inc. (NASDAQ:ATHX) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - July 10 at 2:30 PM
ETFs with exposure to Athersys, Inc. : July 7, 2017ETFs with exposure to Athersys, Inc. : July 7, 2017
finance.yahoo.com - July 8 at 7:02 AM
Athersys And Aurinia Target Human And Animal Health - Seeking AlphaAthersys And Aurinia Target Human And Animal Health - Seeking Alpha
seekingalpha.com - June 27 at 3:50 PM

SEC Filings

Athersys (NASDAQ:ATHX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Athersys (NASDAQ:ATHX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Athersys (NASDAQ ATHX) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.